- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03917069
Nab-PCE vs PC for MM After Failure of Anti-PD-1
April 15, 2019 updated by: Jun GUO, Peking University Cancer Hospital & Institute
Nab-paclitaxel Plus Carboplatin Combined Endostatin Versus Solvent-based Paclitaxel Plus Carboplatin in the Treatment of Advanced Melanoma After the Failure of PD-1 Treatment #A Randomized Controlled, Open, Multicenter Trial
This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin
- Endostatin for advanced melanoma after failure of PD-1 therapy. The aim was to evaluate the efficacy and safety of nab-paclitaxel+carboplatin
- endostatin versus combination of paclitaxel and carboplatin in patients with advanced melanoma after failure of PD-1 therapy.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The enrollment time is expected to be 1.5 year and the observation time is 2 years.
The regimen were performed on a 28-day/21-day cycle respectively.
Subjects who met the entry criteria were treated in a 2:1 group according to a randomized list: the treatment group was treated with nab-paclitaxel + carboplatin + endostatin regimen, and the control group was treated with paclitaxel + carboplatin.
In this trial, the efficacy is evaluated every 8 weeks until disease progression or unacceptable toxicity,or until the investigator deemed that the patient's condition was unacceptable for further treatment.
The follow-up period was 24 months after the end of treatment (follow-up patient survival information and new anti-tumor treatment).
The planning enrolled sample size for nab-paclitaxel + carboplatin + endostatin group and paclitaxel-carboplatin group were 90 patients and 45 patients, respectively.
Study Type
Interventional
Enrollment (Anticipated)
145
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lili Mao, Dr.
- Phone Number: 861013261859885
- Email: yunzhongmanbu7848@163.com
Study Contact Backup
- Name: Lu Si, Dr.
- Phone Number: 861088196956
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Lili Mao, Dr
- Phone Number: 861013261859885
- Email: yunzhongmanbu7848@163.com
-
Contact:
- Lu Si
- Phone Number: 861088196956
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years old, ≤ 70 years old, male or female;
- Histological or pathological diagnosis of advanced melanoma, and progressed after anti-PD-1 treatment (disease progression or unacceptable toxicity);
- The patient has at least one (RECIST 1.1 standard) measurable lesion, which needs to be detected by spiral CT or MRI, and the tumor lesion has at least one single diameter ≥ 1 cm;
- ECOG PS is 0 or 1 (see Annex 1 for standards);
- The estimated survival period is ≥12 weeks;
- no chemotherapy contraindications, including normal peripheral blood, liver and kidney function and electrocardiogram are basically normal; Peripheral blood: neutrophils ≥1.5×109/L, platelets≥90×109/ L, hemoglobin≥90 g/L; Renal function: normal serum creatinine; For patients with non-metastatic liver function impairment: alanine, aspartate aminotransferase ≤ 2.5 ULN, For patients with metastatic liver dysfunction: alanine, aspartate aminotransferase ≤ 5 ULN;
- Patients who have undergone topical treatment for asymptomatic brain metastases can be enrolled and have a clinical stable status of at least 4 weeks.
- Patients voluntarily participate in and sign an informed consent form.
- contraindications for the use of no carboplatin, paclitaxel, entropic and albumin paclitaxel
Exclusion Criteria:
- Known HIV, hepatitis B/C virus positive status or history of active tuberculosis (testing prior to randomisation is not required)
- Received any investigational drug within 28 days or 5 half-lives of the planned first dose of this study treatment.
- Active infection requiring systemic therapy.
- A known history of another malignancy or concurrent malignancy unless the patient is disease-free for a minimum of 1 year, is completely treated and is at low-risk of recurrence.
- Patients with a history or evidence of cardiovascular risk,
- History or evidence of interstitial lung disease or active non-infectious pneumonitis.
- Serious or unstable pre-existing medical conditions or other conditions that could interfere with the patient's safety, consent, or compliance.
- Pregnant or breastfeeding females, or expecting to conceive or father children within the projected period of study treatment (52 weeks followed by 4 months following end of study treatment).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: nab-paclitaxel + endostatin+ carboplatin
nab-paclitaxel + endostatin+ carboplatin nab-paclitaxel 260mg/m2, d1 +Carboplatin AUC=5, d1 +endostatin 15mg, d1-14 q28d
|
nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14,q28d
|
Active Comparator: paclitaxel+carboplatin
paclitaxel+carboplatin paclitaxel 175 mg/m2, d1+ Carboplatin AUC=5, d1 q21d
|
paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: 3 years
|
The time from treatment to tumor progression or death
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: At the end of Cycle 2 (each cycle is 28 days)
|
response evaluation disease progression defined by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) criteria. response (PR), refers to the number of cases with complete and partial response after treatment as a percentage of the total number of evaluable cases |
At the end of Cycle 2 (each cycle is 28 days)
|
Disease Control Rate (DCR)
Time Frame: At the end of Cycle 2 (each cycle is 28 days)
|
The disease control rate was the proportion of patients with complete remission, partial remission and stability (SD) in all patients.
|
At the end of Cycle 2 (each cycle is 28 days)
|
overall survival (OS)
Time Frame: 3 years
|
OS was defined as the time from the date of the first administration of trial regimen to the date of death from any cause (event) or last follow-up (censored data).
|
3 years
|
Adverse events (AE)
Time Frame: 3 years
|
Adverse events (AE) were monitored on an ongoing basis and classified according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0.
Patients were assessed for toxicities before each administration, and toxicity was graded accordingly
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jun Guo, Dr., Peking University Cancer Hospital & Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 23, 2019
Primary Completion (Anticipated)
September 30, 2021
Study Completion (Anticipated)
September 30, 2022
Study Registration Dates
First Submitted
April 12, 2019
First Submitted That Met QC Criteria
April 15, 2019
First Posted (Actual)
April 16, 2019
Study Record Updates
Last Update Posted (Actual)
April 17, 2019
Last Update Submitted That Met QC Criteria
April 15, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019NPCE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified individual participant data for all primary and secondary outcome measures will be made available.
IPD Sharing Time Frame
Data will be available within 6 months of study completion.
IPD Sharing Access Criteria
data access requests will be reviewed by an external Independent Review Panel.Requestors will be required to sign a Data Access Agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Melanoma
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)United States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Regeneron PharmaceuticalsBristol-Myers SquibbCompletedMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
Regeneron PharmaceuticalsBristol-Myers SquibbActive, not recruitingMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
MorphotekTerminatedMelanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic MelanomaUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Metastatic Melanoma | Advanced Non-hematologic MalignanciesUnited States
-
University of Colorado, DenverMerck Sharp & Dohme LLCActive, not recruitingStage IV Melanoma | Advanced Melanoma | Stage III MelanomaUnited States
-
Azienda Ospedaliera di PerugiaNot yet recruitingAdvanced Melanoma | Early MelanomaItaly, Sweden, France, Germany, Netherlands, Poland, Spain
-
Cancer Trials IrelandCompletedMetastatic Melanoma | Advanced MelanomaIreland
-
Yana NajjarBristol-Myers Squibb; PfizerActive, not recruitingUnresectable Melanoma | Advanced MelanomaUnited States
Clinical Trials on Chemotherapeutic Combinations
-
Mashhad University of Medical SciencesUnknownEsophageal NeoplasmsIran, Islamic Republic of
-
First Affiliated Hospital of Zhejiang UniversityCompletedColorectal CancerChina
-
University of MiamiPediatrixTerminatedPremature BirthUnited States
-
Fuzhou General HospitalNot yet recruiting
-
Almirall, S.A.proDERM GmbHCompleted
-
Boston University Charles River CampusMassachusetts General Hospital; University of Michigan; National Institute on...Not yet recruitingAphasia, Primary Progressive | Stuttering, DevelopmentalUnited States
-
Oliver JonasMassachusetts General HospitalCompletedLung Cancer | Lung TumorUnited States
-
Fudan UniversityUnknownTriple Negative Breast CancerChina
-
IVI MadridDiana AlecsandruRecruitingReproductive IssuesSpain
-
Beijing Tiantan HospitalBeijing GeneX Health Technology Co., LtdRecruitingRecurrent High Grade GliomaChina